Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Remark Holdings Announces $6 Million Contract to Deploy an Additional 15,000 AI Driven Terminals for Its Pharmacy Patient Terminal System in 2019

Interactive Online Network Connects Doctors with over 40 Million Patients Annually

Remark Holdings, Inc., a diversified global technology company with leading artificial intelligence (AI) solutions and digital media properties, announced a $6 Millioncontract for 2019 to deploy an additional 15,000 AI Driven Terminals for its Pharmacy Patient Terminal System.

Building upon the successful initial deployment of its AI-driven pharmacy terminal network in Sichuan province in the fourth quarter of 2018, upon which 5,000 Terminals were delivered and recognized as revenue, Remark is expanding its deployment to 30 cities, and 15,000 additional stores, covering more than 10,000 doctors and medical teams and serving over 40 million patients, while issuing more than 100,000 prescription every day. There are approximately 480,000 pharmacies in total in China.

Read More: Affectiva’s Latest $26 Million to Drive the Integration of Emotional Intelligence AI in Safety Systems of Automobiles

Related Posts
1 of 30,123

Remark is providing the membership management system, including facial ID and back-end service platform to support the online-pharmacy terminal network. When patients talk with a doctor via an in-store terminal, Remark’s membership system will acquire the patient’s face, identify the patient and deliver his or her medical history, including previous prescriptions. The system will then automatically provide corresponding doctors with the patient’s portrait analysis, allowing the doctors to diagnose the patient and issue a prescription.

“Our AI-based pharmacy terminal system represents a highly innovative use of our technology in addressing China’soverburdened healthcare system from the standpoint of simplifying everyday doctor/patient interactions and speeding the diagnosis and prescription process,” said Kai-Shing Tao, Chairman and Chief Executive Officer of Remark Holdings. “We’re well underway in deploying our AI-backed retail terminal system and demonstrating the power of our highly accurate facial identification and retail management technology.  As we continue to scale our terminal footprint towards more locations, we expect recurring value-added services revenue to grow as well. This is just one example of our ability to develop highly tailored and accessible AI solutions for multiple industries, with the goal of solving specific issues, driving efficiencies and fostering more informed and successful business and institutional ecosystems.”

Read More: World’s Largest Business Organization Partners with Perlin for Blockchain Adoption Across Its 45 Million Members

Remark’s terminal system allows pharmacies to fully take advantage of the platform and tools to directly prescribe medications to patients after online consultation, supporting a streamlined process and increased revenue. For patients, the terminal system is exempted from the complicated procedures of queuing in hospitals, achieving medical convenience and delivering primary care service at the patient’s fingertips. For the government, all prescription drug information and sales records are stored in the system, which helps to strengthen management of drug purchase and sales and combat sales of recycled drugs in order to ensure medication safety.

Read More: NASA TV Coverage Set for April 17 Cygnus Launch to International Space Station

Leave A Reply

Your email address will not be published.